Jefferies Keeps Their Hold Rating on Novo Nordisk (0QIU)
Jefferies analyst Michael Leuchten maintained a Hold rating on Novo Nordisk yesterday and set a price target of DKK275.00. The company’s shares closed yesterday at DKK251.40.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Leuchten covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and GlaxoSmithKline. According to TipRanks, Leuchten has an average return of -4.5% and a 50.67% success rate on recommended stocks.
In addition to Jefferies, Novo Nordisk also received a Hold from J.P. Morgan’s Richard Vosser in a report issued today. However, yesterday, Goldman Sachs maintained a Buy rating on Novo Nordisk (LSE: 0QIU).
0QIU market cap is currently DKK1383.4B and has a P/E ratio of 13.50.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.
Read More on GB:0QIU:
Disclaimer & DisclosureReport an Issue
- Novo Nordisk confirms reduction in U.S. list prices for semaglutide drugs
- Novo Nordisk to reduce Ozempic, Wegovy list prices by up to 50%, WSJ reports
- Novo Nordisk downgraded to Hold from Buy at Nordea
- Novo Nordisk downgraded to Hold from Buy at Kepler Cheuvreux
- Novo Nordisk downgraded to Neutral from Overweight at JPMorgan
